Edition:
United States

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

17.15USD
18 Aug 2017
Change (% chg)

$0.20 (+1.18%)
Prev Close
$16.95
Open
$16.80
Day's High
$17.55
Day's Low
$16.80
Volume
160,677
Avg. Vol
254,742
52-wk High
$36.80
52-wk Low
$16.00

AMAG.OQ

Chart for AMAG.OQ

About

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia... (more)

Overall

Beta: 1.07
Market Cap(Mil.): $598.14
Shares Outstanding(Mil.): 35.29
Dividend: --
Yield (%): --

Financials

  AMAG.OQ Industry Sector
P/E (TTM): -- 31.59 32.70
EPS (TTM): -1.39 -- --
ROI: -2.17 15.32 14.88
ROE: -4.83 16.34 16.12

BRIEF-Amag Pharmaceuticals Q2 loss per share $0.40

* Amag pharmaceuticals announces second quarter 2017 financial results and provides corporate update

Aug 03 2017

BRIEF-Amag completes feraheme FDA submission for the treatment of all adult patients with iron deficiency anemia

* Amag completes Feraheme® (ferumoxytol) FDA submission for the treatment of all adult patients with iron deficiency anemia

Aug 03 2017

BRIEF-Amag Pharmaceuticals announces commercial availability of Intrarosa (prasterone) at U.S. pharmacies

* Says announces commercial availability of intrarosa (prasterone) at U.S. pharmacies

Jul 24 2017

BRIEF-Amag reports U.S. FDA acceptance of supplemental new drug application for Makena

* Amag announces U.S. FDA filing acceptance of supplemental new drug application for makena® (hydroxyprogesterone caproate injection) subcutaneous auto-injector

Jun 26 2017

BRIEF-Camber Capital Management LLC reports 7.13 pct passive stake in AMAG Pharmaceuticals

* Camber Capital Management LLC reports 7.13 percent passive stake in AMAG Pharmaceuticals Inc as on May 04, 2017 - SEC filing Source text (http://bit.ly/2rj6Y6h) Further company coverage:

May 15 2017

BRIEF-Amag Pharmaceuticals Inc says increased size of offering to $300 mln

* Amag Pharmaceuticals announces pricing of $300 million of 3.25% convertible senior notes due 2022

May 05 2017

BRIEF-AMAG Pharma announces proposed offering of $250 mln of convertible senior notes due 2022

* AMAG Pharmaceuticals Inc announces proposed offering of $250 million of convertible senior notes due 2022

May 03 2017

BRIEF-AMAG Pharmaceuticals says positive topline data from Feraheme label expansion study

* Announces positive topline data from phase 3 feraheme® (ferumoxytol) label expansion study

May 02 2017

BRIEF-AMAG Pharmaceuticals posts Q1 loss per share $1.06

* AMAG Pharmaceuticals announces first quarter 2017 financial results and provides corporate update

May 02 2017

BRIEF-Amag submits supplemental NDA for makena auto-injector

* Amag submits supplemental new drug application to FDA for makena (hydroxyprogesterone caproate injection) auto-injector for subcutaneous use

Apr 17 2017

Earnings vs. Estimates